For general information, Learn About Clinical Studies. Patient must have at least one? Patients who have received one prior regimen must have a GOG performance status of 0, 1, or 2. Recovery from effects of recent surgery, radiotherapy, or chemotherapy.
Patients must have NOT received any non-cytotoxic biologic or targeted agents as part of their primary treatment or for management of recurrent or persistent disease. All patients must have a baseline electrocardiogram completed prior to study entry. Patients who have received prior radiotherapy to any portion of the abdominal cavity or pelvis OTHER THAN for the treatment of cervical cancer within the last three years are excluded.
Patients who have received prior chemotherapy for any abdominal or pelvic tumor OTHER THAN for the treatment of cervical cancer within the last three years are excluded. Patients with uncontrolled or significant cardiovascular disease including any of the following:. Uncontrolled hypertension despite anti-hypertensive therapy. Patients on therapeutic warfarin anticoagulation are excluded. Try the modernized ClinicalTrials.
Learn more about the modernization effort. Hide glossary Glossary Study record managers: refer to the Data Element Definitions if submitting registration or results information. Search for terms. Save this study. Warning You have reached the maximum number of saved studies Brivanib Alaninate in Treating Patients With Persistent or Recurrent Cervical Cancer The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.
Federal Government. Read our disclaimer for details. Results First Posted : January 4, At the beginning of the trial, people with different types of cancer including breast cancer could take part, but now it is only recruiting people with ovarian cancer. Everybody taking part in the trial has brivanib for 12 weeks to begin with. You take up to 4 brivanib tablets every day. You will be asked to keep a diary at home to record when you take your tablets.
If your cancer has grown in size by a quarter or more, you will stop having brivanib and leave the trial. Your doctor will discuss other treatment options with you.
If your cancer has not got much bigger, or much smaller, you will be put into 1 of 2 treatment groups by a computer. Neither you nor your doctor can decide which group you are in. This is called randomisation. People in group 1 carry on having brivanib. People in group 2 have dummy placebo tablets. Neither you nor your doctor will know which group you are in. But if your cancer starts getting bigger during this part of the trial, the trial doctors can find out if you are taking brivanib or placebo tablets.
If are taking the placebo tablets, you can switch back to having brivanib again. The trial doctors will get a sample of tissue removed when you had a biopsy to diagnose cancer.
If there is no tissue available, they may ask you to have another biopsy. And they will get take an extra blood sample at the beginning of the trial. They will use these samples to learn more about how brivanib works and what happens to it in the body.
They will also look at the DNA in your samples to see how genes affect the way people respond to the drug and the side effects they have. You go to hospital once a week for the first 3 weeks of treatment, and then once every 3 weeks after that.
Novel trials are also designed testing drugs in biomarker-based subpopulations of patients with HCC. These strategies have been deemed successful in breast, melanoma, and lung cancers, and are expected to change the landscape of trial design of HCC. Abstract Hepatocellular carcinoma HCC is a major health problem.
0コメント